We showed that L-BORT has better pharmacokinetics and pharmacodynamics with less cytotoxicity in vitro and in vivo, opening a therapeutic window for the application of Sp1 inhibitors, including BORT, in CML subpopulations characterized by BCR/ABL overexpression. Here, SP1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.